Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center

Clinical Infectious Diseases

Volumn 48, Issue 12, 2009, Pages 1724-1728

  Hartzell, Joshua D ^a,c   Neff, Robert ^b   Ake, Julie ^a   Howard, Robin ^c   Olson, Stephen ^b   Paolino, Kristopher ^a   Vishnepolsky, Mark ^b   Weintrob, Amy ^a   Wortmann, Gienn ^a  

^a Infectious Disease Service   (United States)

^b Nephrology Service   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; CREATININE;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CREATININE BLOOD LEVEL; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RISK ASSESSMENT; SIDE EFFECT; TERTIARY HEALTH CARE;

ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLISTIN; FEMALE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE; MALE; UNITED STATES; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 66949152183     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/599225     Document Type: Article

References (20)

1. Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant gram-negative bacterial infections. Lancet Infect Dis 2006;6:589-601.
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
3. Linden PK, Paterson DL. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin Infect Dis 2006; 43(Suppl 2):S89-94.
4. Falagas ME, Kasiakou SK, Tsiodras S, Michalopoulos A. The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature. Clin Med Res 2006; 4:138-46.
5. Falagas ME, Kasiakou SK, Kofteridis DP, Roditakis G, Samonis G. Effectiveness and nephrotoxicity of intravenous colistin for treatment of patients with infections due to polymyxin-only-susceptible (POS) gram-negative bacteria. Eur J Clin Microbiol Infect Dis 2006; 25:596-9.
6. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10:R27.
7. Falagas ME, Rizos M, Bliziotis IA, et al. Toxicity after prolonged (more than four weeks) administration of intravenous colistin. BMC Infect Dis 2005; 5:1.
8. Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33:1162-7.
9. Pintado V, San Miguel LG, Grill F, et al. Intravenous colistin sul- phomethate sodium for therapy of infections due to multidrug-resistant gram-negative bacteria. J Infect 2008;56:185-90.
10. Koch-Weser J, Sidel VW, Federman EB, Kanarek P, Finer DC, Eaton AE. Adverse effects of sodium colistimethate: manifestations and specific reaction rates during 317 courses of therapy. Ann Intern Med 1970; 72:857-68.
11. Tallgren LG, Liewendahl K, Kuhlbaeck B. The therapeutic success and nephrotoxicity of colistin in acute and chronic nephropathies with impaired renal function. Acta Med Scand 1965; 177:717-28.
12. Baines RD Jr, Rifkind D. Intravenous administration ofsodium colisti- methate. JAMA 1964; 190:278-81.
13. Koomanachai P, Tiengrim S, Kiratisin P, Thamlikitkul V. Efficacy and safety of colistin (colistimethate sodium) for therapy of infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii in Siriraj Hospital, Bangkok, Thailand. Int J Infect Dis 2007; 11:402-6.
14. Wortmann G, Weintrob A, Barber M, et al. The evolution of an Aci- netobacter outbreak associated with war trauma. Infect Control Hosp Epidemiol 2008; 29:553-5.
15. Zapor M, Erwin D, Erwowele G, Wortmann G. Emergence of multidrug resistance in bacteria and impact on antibiotic expenditure at a major army medical center caring for soldiers wounded in Iraq and Afghanistan. Infect Control Hosp Epidemiol 2008; 29:661-3.
16. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, ADQI workgroup. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-12.
17. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron Clin Pract 2008; 109:c182-7.
18. Levin AS, Barone AA, Penco J, et al. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28: 1008-11.
19. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: a prospective evaluation. Int J Antimicrob Agents 2005; 26:504-7.
20. Berg JR, Spilker CM, Lewis SA. Modulation of polymyxin B effects on mammalian urinary bladder. Am J Physiol 1998; 275:F204-15.